AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02332928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Study NCT02332928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Study NCT04578626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
Study NCT01015521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoflavone Prodrug
Description: Aminoflavone Prodrug administered D1, D8 of 21-day cycle
Study NCT02996396 — intervention group
Intervention type: DEVICE
Intervention: Nellix Endovascular Aneurysm Sealing System (Nellix®-System)
Description: The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
Study NCT02194790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Integrated CKD Care
Description: Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
Study NCT03237806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedated
Description: Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
Study NCT03237806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light sedated
Description: Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
Study NCT01334554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20 mg three times a day.
Study NCT01334554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active drug
Study NCT00598650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
Study NCT04754763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentin-Bonding Agents
Description: 3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
Study NCT04754763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
Study NCT01628913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 400 mg bid p.o. (by mouth, twice daily)
Study NCT01628913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10 mg qd p.o. (by mouth, daily)
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT00011986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02015247 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: computer-assisted surgery
Description: use of computer-assisted navigation during periacetabular osteotomy
Study NCT00905229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytonadione
Description: 2.5 mg po
Study NCT00905229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytonadione
Description: 0.5 mg IV
Study NCT04391712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLS Laser
Description: Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
Study NCT00595413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
Study NCT04391712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Inpatient Medical Care
Description: Regular inpatient medical care
Study NCT01426061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology plus conventional treatment
Description: Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
Study NCT01426061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy plus conventional treatment
Description: Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
Study NCT01426061 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Conventional treatment
Description: Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
Study NCT03502564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for ED
Description: Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
Study NCT03502564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent CBT for ED and PTSD
Description: The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
Study NCT01606579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: According to local standard
Study NCT01606579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724 in combination with dasatinib
Study NCT01606579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: PRI-724 in combination with low dose ara-C therapy
Study NCT02441842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Description: administered 60 minutes pre procedure
Study NCT02441842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: administered 60 minutes pre procedure
Study NCT02441842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: administered 60 minutes pre procedure
Study NCT03730584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath.
Study NCT03730584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
Study NCT00372957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823093 15mg
Description: White opaque capsule containing 15mg of GW823093 as free base
Study NCT00372957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823093 placebo capsule
Description: Matching placebo of GW823093 capsule or 15mg capsule
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: According to local standard
Study NCT00372957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093 placebo capsule
Description: Matching placebo of GW823093 capsule or 15mg capsule
Study NCT00372957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823093 30mg
Description: White opaque capsule containing 15mg of GW823093 as free base
Study NCT02701764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Study NCT02701764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00781547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human growth hormone
Description: The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
Study NCT00781547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
Study NCT03246087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupunture
Description: acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed.
Study NCT03246087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupunture
Description: acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed.
Study NCT03246087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: standard of care home exercise program
Study NCT04160104 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
Study NCT04160104 — intervention group
Intervention type: OTHER
Intervention: Questionnair
Description: Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
Study NCT00352300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy
Study NCT00352300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00352300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00352300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given IV
Study NCT03816189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
Study NCT03816189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsies
Description: In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
Study NCT01047189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate 1.2% and tretinoin 0.025%
Description: applied once daily for 12 weeks
Study NCT01047189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin 1% gel
Description: Topical clindamycin applied each morning for 12 weeks
Study NCT01047189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin 0.025% cream
Description: Tretinoin 0.025% cream each evening for 12 weeks
Study NCT02332187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active electrical stimulation using an All Stim stimulator
Description: This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
Study NCT02570529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albis®
Description: The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Study NCT02570529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Study NCT02189590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
Study NCT02189590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q
Description: Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
Study NCT03782636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion
Study NCT03782636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile diluent used for the aldesleukin preparation and 5% glucose
Study NCT02871401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Study NCT02332187 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electrical stimulation using an All Stim stimulator
Description: With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
Study NCT01370187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 4mg daily for 2 months
Study NCT00595413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept: with loading dose
Description: Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
Study NCT03407092 — intervention group
Intervention type: OTHER
Intervention: ADAPT cohort
Description: Thrombectomy with distal aspiration technique
Study NCT03407092 — intervention group
Intervention type: OTHER
Intervention: Stentriever Cohort
Description: Thrombectomy with stent retriever
Study NCT04515888 — intervention group
Intervention type: OTHER
Intervention: PFDI-20 / PFIQ-7 questionnaires
Description: PFDI-20 / PFIQ-7 questionnaires (one shot)
Study NCT02871401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Study NCT01049373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDC
Description: (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
Study NCT01049373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 10 drops, t.i.d, 15 weeks
Study NCT03030456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Plate®
Description: Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
Study NCT01805284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
Study NCT03663855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin
Description: Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
Study NCT04343092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Description: Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
Study NCT01148667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein hydrolysate added with LGG
Description: Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
Study NCT03522883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate intake prior to exercise
Description: Participants will be submitted to carbohydrate supplementation prior to exercise
Study NCT01148667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infants drink casein hydrolysate without LGG
Description: Infants drink extensively hydrolysed casein formula without added LGG
Study NCT03522883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate intake prior to exercise
Description: Participants will be submitted to carbohydrate supplementation prior to exercise
Study NCT03522883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate intake prior to exercise
Description: Participants will be submitted to carbohydrate supplementation prior to exercise
Study NCT03712800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmical massage
Description: Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
Study NCT00595413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
Study NCT02860442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone brief intervention (SP-BI)
Description: Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan.